Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 12/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292061 | 1.00 | KCNE1 (1.00) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL29389863 | 1.00 | KCNE1 (1.00) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL4292064 | 1.00 | KCNE1 (1.00) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6561056 | 0.93 | KCNE1 (1.00) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6561055 | 0.93 | KCNE1 (1.00) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6561052 | 0.93 | KCNE1 (1.00) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6559944 | 0.88 | KCNE1 (0.79) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6559948 | 0.88 | KCNE1 (0.79) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6559939 | 0.88 | KCNE1 (0.79) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6560812 | 0.87 | KCNE1 (0.78) | KCNE1KCNQ1MEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | claimed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | claimed |
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | LIEBER INSTITUTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20180328915-A1 | Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-15 | — | — | US | disclosed |
| WO-2017075222-A1 | TREATMENT OF NEUROLOGICAL AND NEURODEVELOPMENTAL DISEASES AND DISORDERS ASSOCIATED WITH ABERRANT ION CHANNEL EXPRESSION AND ACTIVITY | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | FIBROSTATIN, S.L. (ES) | 2015-11-12 | — | — | US | disclosed |
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | disclosed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | disclosed |
| US-20090227469-A1 | CELLS AND ASSAYS FOR USE IN DETECTING LONG QT SYNDROME | THE J. DAVID GLADSTONE INSTITUTES | 2009-09-10 | — | — | US | disclosed |
| EP-1140042-B1 | UTILIZATION OF INHIBITORS OF THE KQT1 CHANNEL IN ORDER TO PRODUCE A MEDICAMENT FOR TREATING DISEASES WHICH ARE CAUSED BY PARASITIC HELMINTHS AND ECTOPARASITES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-0807629-B1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | KCNQ1, KCNQ2, KCNQ3 | KCNE1 38/4885KCNQ1 1/4885MEN1 2614/4885 |
| US-20180328915-A1 | Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity | KCNQ1, KCNQ2, KCNQ3 | KCNE1 38/4885KCNQ1 1/4885MEN1 2614/4885 |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | KCNE1 2388/4885KCNQ1 3574/4885MEN1 4339/4885 |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | KCNE1 2388/4885KCNQ1 3574/4885MEN1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.